| Cell Line Description |
Farage is a B lymphocyte cell line isolated in 1990 from a Caucasian adult female patient with non-Hodgkin B cell lymphoma. The cells lack both T and myeloid surface markers, express B cell surface antigens including CD19, CD20, CD22, HLA-DR, were positive for C3 receptors and EBNA and expressed BCL-2. No immunoglobulin determinants could be demonstrated on the cell surface. When treated with interleukin 4 (IL-4), Farage cells exhibit increased expression of several markers including CD23, CD54, and CD58, along with decreased levels of CD21, CD22, and CD38. This modulation of surface markers suggests a role for IL-4 in influencing B cell behavior and provides a useful model for exploring signaling pathways and regulatory mechanisms in B cells. The response to phorbol 12-myristate 13-acetate (PMA) treatment, which results in the down-regulation of CD21 and CD23, further supports its application in studying kinase-driven signaling in B-cells. Additionally, the presence of Epstein-Barr virus (EBV) in these cells allows for the study of viral interactions with host cell machinery, particularly in the context of lymphocyte oncogenesis. |
中文
